

## Learner Notification

### MED Learning Group

#### Strategies to Overcome Endocrine Therapy Resistance in HR+/HER2-negative Breast Cancer

January 31, 2024 – January 31, 2025

Online

### Acknowledgement of Financial Commercial Support

Eli Lilly

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hours.

### Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-24-013-H01-P / JA4008163-9999-24-013-H01-T

***NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.***

### Objectives - After Attending This Program You Should Be Able To

1. Formulate a plan to support a patient's consistent, chronic, and tolerable use of oral anti-cancer medications for HR+/HER2-negative breast cancer.
2. Critically analyze CDK 4/6 inhibitor clinical trials data in early HR+/HER2-negative breast cancer to optimize the monitoring and management of treatment-associated adverse events.
3. Develop strategies to support the patient's adherence and persistence with agreed upon treatment for HR+/HER2-negative early breast cancer.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Laura	Aibara	NA
Daniel	DaSilva	NA
Matthew	Frese	NA
Christina	Gallo	NA

Lisa	Kuhns	NA
Nicole	Longo	NA
Erica	Mayer	AstraZeneca, Lilly, Novartis: Consultant
Jessica	McMullen	NA
Jo	Shultz	NA
Geoffrey	Wall	Janssen: Speakers Bureau
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)